Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug 23:10:8.

A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies

Amanda P Liggins  1 , Seah H Lim, Elizabeth J Soilleux, Karen Pulford, Alison H Banham
Affiliations

A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies

Amanda P Liggins et al. Cancer Immun. .

Abstract

Cancer-testis (CT) antigens/genes show restricted expression in normal tissues but widespread expression in many tumour types. This, coupled with their ability to induce cytotoxic T-lymphocyte responses, makes them attractive vaccine candidates. Following our identification of PASD1, we have used RT-PCR to analyse the mRNA expression profile of a large panel of CT genes in cell lines derived from haematological malignancies, and have studied Sp17 protein expression in the same cell lines and diffuse large B-cell lymphoma (DLBCL) biopsies. Our extensive analysis revealed multiple CT transcripts exhibiting widespread expression across cell lines derived from 21 B- and 4 T-cell malignancies. The broadest mRNA expression profiles were observed for the following eight CT genes: Sp17 (25/25), PRAME (25/25), CSAGE (24/25), PASD1 (22/25), CAGE/DDX53 (19/25), CTAGE1 (19/25), HAGE/DDX43 (16/25) and PLU-1/JARID1B (15/25). Cell lines derived from more aggressive lymphoma subtypes generally expressed CT transcripts at higher frequency. Sp17 protein was detected in a number of cell lines and in six of eleven (54.5%) DLBCL biopsies. Analysis of Sp17 protein expression, by immunohistochemistry and Western blotting, broadens the scope of this CT antigen as a potentially relevant clinical target in haematological malignancies. Further studies of protein expression are now needed to validate these antigens as vaccine candidates.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Table 1
Table 1
Expression of CT transcripts in cell lines derived from DLBCL as assessed by RT-PCR.
Table 2
Table 2
Expression of CT transcripts in cell lines derived from non-DLBCL B-cell and T-cell malignancies as assessed by RT-PCR.
Figure 3
Figure 3
Figure 4
Figure 4
Table 3
Table 3
Primer sequences and annealing temperatures used in RT-PCR analyses of CT transcripts.
See this image and copyright information in PMC

References

    1. Ng AK. Diffuse large B-cell lymphoma. Semin Radiat Oncol. 2007;17:169–175. - PubMed
    1. Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Current management of mantle cell lymphoma. Drugs. 2007;67:1689–1702. - PubMed
    1. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist. 2007;12:664–689. - PubMed
    1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999;10:1419–1432. - PubMed
    1. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311:1471–1475. - PubMed

Publication types

LinkOut - more resources